Veru (VERU) said Monday it has completed enrollment in a phase 2 trial evaluating its experimental drug, enobosam, in combination with semaglutide, in about 200 adults aged 65 and older with obesity.
The company said the study will evaluate whether the combination drug will help patients lose more weight while preserving muscle mass, physical function and bone density during semaglutide treatment.
The main goal is to measure changes in body weight after 68 weeks of treatment, the company said.
Interim results, including data on muscle and fat mass, are expected in Q1 2027, with final topline results scheduled in Q4 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments